Core F: Biomarker Core

核心 F：生物标志物核心

• 批准号: 10652573
• 负责人: LEE E. GOLDSTEIN
• 金额: $ 33.13万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10652573
• 关键词: Address; Ally; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; Amyloid; Amyloid beta-Protein; Atrophic; Biological Markers; Biometry; Blood; Boston; Brain imaging; Cells; Cerebrum; Clinical; Clinical Research; Collaborations; Communities; Data; Dementia; Detection; Development; Diagnosis; Differential Diagnosis; Disease; Doctor of Medicine; Doctor of Philosophy; Early Diagnosis; Early Intervention; Early treatment; Education; Emerging Technologies; Faculty; Generations; Goals; Hippocampus; Human; Image; Imaging Techniques; Institution; International; Ligand Binding; Light; Liquid substance; MRI Scans; Magnetic Resonance Imaging; Measures; Mentorship; Mission; Molecular Profiling; Monitor; National Institute on Alcohol Abuse and Alcoholism; Nerve Degeneration; Neurobehavioral Manifestations; Neurodegenerative Disorders; Neurons; Participant; Peptides; Plasma; Positron-Emission Tomography; Postdoctoral Fellow; Process; Protocols documentation; Qualifying; Research; Research Personnel; Resources; Risk Assessment; Scientist; Serum; Specimen; Staging; Targeted Research; Testing; Therapeutic; Thick; Training; United States National Institutes of Health; Universities; Update; Ventricular; accurate diagnosis; biomarker development; biomarker discovery; biomarker validation; brain volume; chronic traumatic encephalopathy; clinical development; cohort; cost effective; data management; data sharing; early-career faculty; education research; entorhinal cortex; exosome; experience; genetic profiling; improved; insight; interest; member; multimodality; neurofilament; neuroimaging; neuroimaging marker; neuropathology; next generation; normal aging; novel; personalized medicine; pre-clinical; prevent; research clinical testing; response; statistics; tau Proteins; tau-1; white matter

Biomarkers provide important information for early detection, differential diagnosis, and disease monitoring of Alzheimer’s disease (AD) and AD-related dementias (ADRDs), including chronic traumatic encephalopathy (CTE). The newly established Biomarker Core of the Boston University Alzheimer’s Disease Research Center (BU ADRC) will be led by three clinician-scientists with experience in biomarker development and validation: Lee Goldstein, M.D., Ph.D. and Wendy Qiu, M.D., Ph.D., who will serve as co-leaders, and Ronald Killiany, Ph.D., who will lead the neuroimaging component. The Biomarker Core will leverage their expertise and existing institutional resources to focus on fluid biospecimen and neuroimaging biomarkers relevant to Alzheimer’s disease (AD) and related dementias (ADRD), including chronic traumatic encephalopathy (CTE). The goal of the Biomarker Core is to collaborate with other cores and centralize biomarker initiatives to support the BU ADRC mission to improve early and accurate diagnosis, differentiation, and monitoring of AD and ADRDs, including CTE. The new Biomarker Core will bank, distribute, and analyze fluid biospecimens and neuroimaging data for shared use by investigators within and outside the BU ADRC and allied national consortia. We will focus on established biofluid and neuroimaging biomarkers (Amyloid-Tau-Neurodegeneration A/T/N NIA-AA Research Framework) with the goal of identifying differences between AD and ADRDs. The Core will also conduct discovery-based development of novel emerging biofluid and neuroimaging biomarkers to enable earlier and more accurate detection, differential diagnosis, staging, and tracking of AD and ADRDs across the disease spectrum. Four Specific Aims are proposed. Aim 1: Process, bank, and distribute fluid biospecimens and neuroimaging data. Aim 2: Measure and analyze established biomarkers (A/T/N NIA-AA Research Framework). Aim 3: Conduct discovery and development of emerging biomarkers, including analysis of blood-derived exosomes and multimodal computational strategies for neuroimaging data. Aim 4: Train next-generation AD biomarker and neuroimaging research leaders. We anticipate that the new Biomarker Core will strengthen BU ADRC research, promote sharing of fluid and neuroimaging biomarker resources, harmonize with efforts to advance national AD/ADRD initiatives, and provide new new insights and biometrics for personalized medicine approaches to diagnose, treat, and prevent AD and ADRD.

生物标志物为疾病的早期检测、鉴别诊断和疾病监测提供重要信息。 阿尔茨海默病 (AD) 和 AD 相关痴呆 (ADRD)，包括慢性创伤性脑病 （热膨胀系数）。波士顿大学阿尔茨海默病研究中心新成立的生物标志物核心 （BU ADRC）将由三名具有生物标志物开发和验证经验的临床科学家领导：Lee 戈德斯坦，医学博士，博士和 Wendy Qiu 医学博士、博士将担任联合领导者，以及 Ronald Killiany 博士 谁将领导神经影像部分。生物标记核心将利用他们的专业知识和现有的 机构资源重点关注与阿尔茨海默病相关的液体生物样本和神经影像生物标志物 疾病（AD）和相关痴呆（ADRD），包括慢性创伤性脑病（CTE）。的目标 生物标记核心将与其他核心合作并集中生物标记计划以支持 BU ADRC 使命是改善 AD 和 ADRD 的早期、准确诊断、鉴别和监测，包括 热膨胀系数。新的生物标记核心将存储、分发和分析液体生物样本和神经影像数据 BU ADRC 内部和外部的调查人员以及联盟国家财团共享使用。我们将重点关注 已建立的生物流体和神经影像生物标志物（淀粉样蛋白-Tau-神经变性 A/T/N NIA-AA 研究 框架），目的是识别 AD 和 ADRD 之间的差异。核心还将进行 基于发现的新型生物流体和神经影像生物标志物的开发，以实现更早和更 更准确地检测、鉴别诊断、分期和跟踪整个疾病的 AD 和 ADRD 光谱。提出了四个具体目标。目标 1：处理、储存和分发液体生物样本 神经影像数据。目标 2：测量和分析已建立的生物标志物（A/T/N NIA-AA 研究框架）。 目标 3：发现和开发新兴生物标志物，包括血液来源的分析 外泌体和神经影像数据的多模式计算策略。目标 4：训练下一代 AD 生物标志物和神经影像研究领导者。我们预计新的 Biomarker Core 将加强 BU ADRC 研究，促进液体和神经影像生物标志物资源共享，协调努力 推进国家 AD/ADRD 计划，并为个性化医疗提供新的见解和生物识别 诊断、治疗和预防 AD 和 ADRD 的方法。